Hims & Hers’ menopause offering expands addressable market, says BofA

Hims & Hers officially launched its menopause and perimenopause service, offering personalized plans that include prescription hormone replacement therapies such as estradiol and progesterone to address symptoms like hot flashes and sleep issues, BofA tells investors in a research note. The launch broadens the Hers brand’s reach into a multi-billion-dollar market, supports revenue diversification amid pressure on the men’s segment, and is expected to provide modest financial contributions in Q4 before ramping into 2026. BofA maintains an Underperform rating and $28 price target on the shares.